Drug profile · INN
elinzanetant
LYNKUET
elinzanetant (LYNKUET) is a neurokinin 3 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — elinzanetant
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
elinzanetant (LYNKUET) is a neurokinin 3 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurokinin 3 receptor antagonist
Primary target: Substance-P receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is elinzanetant?
elinzanetant (LYNKUET) is a neurokinin 3 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for elinzanetant?
LYNKUET is a marketed brand name for elinzanetant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elinzanetant?
elinzanetant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.